CD52 Expression

Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cells such as lymphocytes, monocytes, eosinophils and dendritic cells. The proliferation of CD52 markers enables researchers to distinguish between healthy and cancerous cells in the medical field. The peptide length of CD52 is 12 amino acid which is anchored to glycosylphosphatidylinositol. As a result of its negative charge researchers believe this molecule has an anti-adhesion function, allowing cells to migrate freely. It is known that CD52 binds with the immunoreceptor tyrosine based inhibitory motif that contains sialic acid binding lectin.

CD52 is found on white blood cells, dendritic cells and monocyte cells.The function of CD52 is not fully known but it is present on chronic lymphocytic leukemia (CLL) and B-cell Non-Hodgkin’s lymphoma (B-NHL) cancer cells. CD52 marker is also found on the surface of immune cells that have been affected by an autoimmune disease.

CD52 marker is used to treat certain types of arthritis and lupus. In addition, it can be used to monitor a patient's response to treatment because CD52 marker levels tend to decrease as the patient recovers from their autoimmune disease. CD52 marker testing is currently being tested for detecting macular degeneration in its early stages before it can cause blindness. CD52 marker therapies are currently being developed for Alzheimer's disease and multiple sclerosis and CD52 is used to treat certain types of arthritis and lupus. CD52 markers can be used to identify CD52 antigen in a sample, such as blood, tissue or fluid, using CD52 antibody labeling. Alemtuzumab is an anti-CD52 recombinant humanized monoclonal antibody which is used for the treatment of B-cell chronic lymphocytic leukemia.

Because the CD52 marker is an important component of CD52 immunotherapy for treating cancer, it allows oncologists to restrict their treatment to only tumorous, CD52-expressing cells. CD52 marker is also used in CD52 stem cell transplantation for treating cancers, such as leukemia and lymphoma. You can remove CD52 marker positive cells from a patient's body and then reintroducie healthy CD52 markers cells after chemotherapy or radiation therapy.